Emerging Therapies in Oncology (2025)

Note: This page is educational and reflects the state of the literature in 2025. It does not replace medical advice.

TL;DR

What's "emerging" in oncology in 2025 is not one thing — it's a portfolio of converging technologies: expanded checkpoint blockade, next-generation CAR-T / CAR-NK / TIL, antibody-drug conjugates (ADCs), bispecific antibodies and T-cell engagers, personalized mRNA cancer vaccines, liquid biopsy for early detection and MRD, gene editing (CRISPR / base / prime), radioligand therapy, and AI-augmented decision support. Most are research-stage or limited to specific indications; a few are already standard of care. Reading the field requires distinguishing approved from promising from press-release.

1. Map of the field

Modality	Status (2025)	Where it's strongest
Checkpoint inhibitors (PD-1/PD-L1, CTLA-4)	Standard of care	Melanoma, NSCLC, urothelial, MSI-H, kidney, head & neck
Anti-LAG-3, anti-TIGIT, anti-TIM-3	Approved (LAG-3) / advanced trials	Melanoma (relatlimab + nivolumab) and combinations
CAR-T (hematologic)	Six FDA-approved products[1]	B-ALL, LBCL, MM, FL, MCL, CLL
CAR-T (solid tumors)	Investigational[2]	Glioma, gastric, sarcoma — early signals
CAR-NK / off-the-shelf	Phase I–II	Multiple
TIL therapy	First approval 2024 (lifileucel)[1]	Melanoma
TCR-T	First approval 2024 (afami-cel)[1]	Synovial sarcoma
ADCs	Mainstream, expanding[3][4]	HER2-low/HER2+ breast, urothelial, gastric, lung
Bispecific antibodies / engagers	Multiple approvals[5]	LBCL, MM, SCLC, melanoma, prostate (under study)
Personalized mRNA vaccines	Phase II/III[6]	Melanoma, pancreatic — combined with checkpoint
CRISPR / base / prime editing	Phase I–II	Sickle cell approved; cancer indications emerging
Radioligand therapy	Approved in select	Prostate (Lu-PSMA), neuroendocrine (Lu-DOTATATE)
Liquid biopsy / MRD	Increasing clinical use	Colorectal, breast, hematologic adjuvant
AI / digital pathology	Tools approved	Imaging triage, pathology assist

For depth on specific items see Biologics 101, CAR-T breakthroughs, and the experimental/ section.

2. Immune checkpoint combinations and next-generation immunotherapy

PD-1/PD-L1 + CTLA-4 was the first dual blockade to gain wide use. The 2024–2025 wave includes:

Anti-LAG-3 (relatlimab) + nivolumab approved in melanoma; ongoing in other indications.
Anti-TIGIT (tiragolumab, vibostolimab) — late-stage trials; mixed results so far.
Anti-TIM-3, anti-VISTA, anti-CD47 — earlier stages.
Costimulatory agonists (ICOS, GITR, OX40, 4-1BB) — independently or with PD-1 blockade.
Cytokine engineering (engineered IL-2, IL-15, IL-12) — rebalancing pathways without systemic toxicity.

Combined immunotherapy expands benefit but also stacks immune-related adverse events (irAEs). irAE management is itself an emerging clinical specialty.

3. ADCs and bispecifics: the workhorses of the next decade

ADCs combine antibody specificity with cytotoxic payload — see Biologics 101 for engineering details. The most consequential 2024–2025 examples:

Trastuzumab deruxtecan (T-DXd) — redefined HER2-low breast cancer; expanded into lung, gastric. Sources: [4]
Sacituzumab govitecan — Trop-2 ADC in TNBC and urothelial.
Enfortumab vedotin — first-line urothelial in combination with pembrolizumab.

Bispecifics expanding: teclistamab and elranatamab (BCMA × CD3, MM); glofitamab, epcoritamab (CD20 × CD3, NHL); tarlatamab (DLL3 × CD3, SCLC); tebentafusp (gp100 × CD3, uveal melanoma). Sources: [5]

4. mRNA cancer vaccines

The mRNA platform born from COVID is being aimed at oncology. Two thrusts:

Personalized neoantigen vaccines — sequencer the patient's tumor, predict mutated peptides likely to be presented on HLA, manufacture an mRNA vaccine encoding those peptides, prime T cells. Combined with checkpoint inhibitors. mRNA-4157 + pembrolizumab in resected high-risk melanoma showed encouraging Phase II RFS data in 2023; Phase III ongoing. Sources: [6]
Shared-antigen vaccines — off-the-shelf, targeting common tumor antigens (e.g., KRAS-G12 mutants).

No mRNA cancer vaccine is approved yet; multiple Phase II/III readouts are expected through 2025–2027. Sources: [6]

5. Gene editing in oncology

Ex vivo — gene-edit T cells to make safer/more potent CAR-Ts (knock out PD-1, TCR, HLA).
In vivo — direct delivery of CRISPR machinery via LNPs (early human trials in liver-targeted indications; cancer indications behind sickle cell).
Base / prime editing — finer changes than double-strand-break CRISPR; lower off-target risk; oncology applications mostly preclinical.

Safety questions specific to cancer applications: off-target editing, chromothripsis-like events observed at high editing rates, insertional mutagenesis in viral-vector approaches.

6. Radioligand therapy (theranostics)

Couple a tumor-targeting peptide or antibody to a therapeutic isotope (β-emitter ¹⁷⁷Lu, α-emitter ²²⁵Ac):

¹⁷⁷Lu-PSMA-617 — approved for metastatic castration-resistant prostate cancer.
¹⁷⁷Lu-DOTATATE — approved for somatostatin-receptor-positive neuroendocrine tumors.
Many more in clinical development — FAP, integrin targets, HER2 conjugates, alpha-emitter constructs.

The "theranostic" framing is powerful: same target, two payloads — one diagnostic (PET), one therapeutic. This aligns drug development with imaging biomarkers naturally. Brazilian context: limited domestic radiopharmaceutical infrastructure is a real bottleneck.

7. Liquid biopsy for MRD and early detection

Two distinct uses, often confused:

MRD (minimal residual disease) — after curative-intent therapy, detect remaining disease via ctDNA. Approved/used in CRC adjuvant decisions, breast, and increasingly in solid tumors. High specificity; sensitivity depends on tumor shedding.
Multi-cancer early detection (MCED) — screen healthy populations for cancer signal in plasma cfDNA. Galleri (GRAIL), commercially available in some markets but not yet approved by FDA; ongoing prospective evaluation. Big sensitivity/specificity trade-offs and equity questions.

8. AI-augmented decision support and digital pathology

Pathology — FDA-cleared digital pathology systems and AI-assist for prostate, breast, colon.
Radiology — AI for breast mammography triage, lung nodule detection, response assessment. Sources: [7]
Genomic interpretation — automated variant tiering, treatment matching against ClinicalTrials.gov.
Foundation models for oncology multimodal data — growing literature, mostly early-stage.

For pitfalls and how not to get fooled by validation theater, see ML pitfalls in oncology.

9. How to read "breakthrough" claims in 2025

Three filters worth applying:

What stage? Phase I expansion ≠ Phase III approval. Press releases obscure this.
What population? Eligibility criteria can make an "all-comers" headline misleading.
What was the comparator? Single-arm responses are not the same as randomized superiority.

The recurring lesson from this list of emerging therapies: most of these will fail or be repurposed; a few will reshape practice. The job of someone working in this space — clinical, technical, or both — is to distinguish them honestly.

References

Brudno JN, Maus MV, Hinrichs CS. CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review. JAMA 2024;332:1924-1935. PMID 39495525. https://doi.org/10.1001/jama.2024.19462
Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol 2024;21:1089-1108. PMID 39134804. https://doi.org/10.1038/s41423-024-01207-0
Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the "biological missile" for targeted cancer therapy. Signal Transduct Target Ther 2022;7:93. PMID 35318309. https://doi.org/10.1038/s41392-022-00947-7
Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov 2023;22:641-661. PMID 37308581. https://doi.org/10.1038/s41573-023-00709-2
Meyer ML, Fitzgerald BG, Paz-Ares L, et al. New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet 2024;404:803-822. PMID 39121882. https://doi.org/10.1016/S0140-6736(24)01029-8
Sayour EJ, Boczkowski D, Mitchell DA, Nair SK. Cancer mRNA vaccines: clinical advances and future opportunities. Nat Rev Clin Oncol 2024;21:489-500. PMID 38760500. https://doi.org/10.1038/s41571-024-00902-1
Adams SJ, Mikhael P, Wohlwend J, et al. Artificial Intelligence and Machine Learning in Lung Cancer Screening. Thorac Surg Clin 2023;33:401-409. PMID 37806742. https://doi.org/10.1016/j.thorsurg.2023.03.001
U.S. National Cancer Institute. https://www.cancer.gov/about-cancer/understanding/what-is-cancer
American Cancer Society. https://www.cancer.org/cancer.html
Cleveland Clinic. Cancer (overview). https://my.clevelandclinic.org/health/diseases/12194-cancer
A.C. Camargo Cancer Center. https://accamargo.org.br
Fundação do Câncer (Brasil). https://www.cancer.org.br/
Ministério da Saúde / BVS. ABC do câncer. https://bvsms.saude.gov.br/bvs/publicacoes/abc_do_cancer.pdf

Emerging Therapies in Oncology (2025) ​

TL;DR ​

1. Map of the field ​

2. Immune checkpoint combinations and next-generation immunotherapy ​

3. ADCs and bispecifics: the workhorses of the next decade ​

4. mRNA cancer vaccines ​

5. Gene editing in oncology ​

6. Radioligand therapy (theranostics) ​

7. Liquid biopsy for MRD and early detection ​

8. AI-augmented decision support and digital pathology ​

9. How to read "breakthrough" claims in 2025 ​

See also ​

References ​